Condition: Atypical Hemolytic Uremic Syndrome · Sponsor: Novartis Pharmaceuticals
The purpose of this Phase 3 study is to evaluate the efficacy and safety of iptacopan upon switching from anti-C5 antibody to iptacopan treatment in study participants with aHUS.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Nanjing, Jiangsu, China | Withdrawn |
| Novartis Investigative Site | Beijing, China | Active Not Recruiting |
| Novartis Investigative Site | Beijing, China | Active Not Recruiting |
| Novartis Investigative Site | Shanghai, China | Withdrawn |
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Paris, France | Recruiting |
| Novartis Investigative Site | Rouen, France | Recruiting |
| Novartis Investigative Site | Toulouse, France | Recruiting |
| Novartis Investigative Site | Tours, France | Recruiting |
| Novartis Investigative Site | Essen, Germany | Recruiting |
| Novartis Investigative Site | Kiel, Germany | Recruiting |
+ 19 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05935215